Advertisement

Pediatric (Non-CNS) Tumors

  • David R. Raleigh
  • Daphne A. Haas-Kogan
  • Steve E. Braunstein
Chapter

Abstract

This chapter will discuss management of pediatric tumors including Wilms’ tumor, neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma, pediatric Hodgkin’s lymphoma, and retinoblastoma.

Keywords

Wilms’ tumor Neuroblastoma Rhabdomyosarcoma Ewing’s sarcoma Pediatric Hodgkin’s lymphoma Retinoblastoma 

Notes

Acknowledgment

We thank Stuart Y. Tsuji MD, PhD, and Linda W. Chan, MD, for their work on the prior edition of this chapter.

References

Wilms’ Tumor

  1. Dome JS, Graf N, Geller JI, et al. Advances in wilms tumor treatment and biology: progress through international collaboration. JCO. 2015;33(27):2999–3005.CrossRefGoogle Scholar

Neuroblastoma

  1. Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26(5):682–94.CrossRefGoogle Scholar
  2. Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric oncology group stage C neuroblastoma. J Clin Oncol. 1991;9:789–95.CrossRefGoogle Scholar
  3. Caussa L, Hijal T, Michon J, et al. Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single-institution study. Int J Radiat Oncol Biol Phys. 2011;79:214–9.CrossRefGoogle Scholar
  4. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971–4.CrossRefGoogle Scholar
  5. Cheung NV, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264–70.CrossRefGoogle Scholar
  6. Jacobson AF, Deng H, Lombard J, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010;95(6):259–2606.CrossRefGoogle Scholar
  7. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children’s oncology group. J Clin Oncol. 2005;23:6459–65.CrossRefGoogle Scholar
  8. McCabe MG, Backlund LM, Leong HS, et al. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neurooncol. 2010;13(4):376–83.CrossRefGoogle Scholar
  9. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a pediatric oncology group study. J Clin Oncol. 1988;6:1271–9.CrossRefGoogle Scholar
  10. Park JR, Kreissman SG, London WB, et al. A phase 3 randomized clinical trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cell as consolidation therapy for high-risk neuroblastoma: a children’s oncology group study. 2016 ASCO Annual Meeting. Abstract LBA3. 2016.Google Scholar
  11. Paulino AC. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol. 2003;20:111–7.CrossRefGoogle Scholar
  12. Peifer M, Hertwig F, Roeis F, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526(7575):700–4.Google Scholar
  13. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol. 2000;18:18–26.CrossRefGoogle Scholar
  14. Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17.CrossRefGoogle Scholar

Rhabdomyosarcoma

  1. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009;27(31):5182–8.CrossRefGoogle Scholar

Ewing’s Sarcoma

  1. Talleur AC, Navid F, Spunt SL, McCarville MB, Wu J, Mao S, Davidoff AM, Neel MD, Krasin MJ. Limited margin radiation therapy for children and young adults with Ewing sarcoma achieves high rates of local tumor control. Int J Radiat Oncol Biol Phys. 2016;96(1):119–26.CrossRefGoogle Scholar

Pediatric Hodgkin’s Lymphoma

  1. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkins disease. J Clin Oncol. 2007;25:332–7.CrossRefGoogle Scholar
  2. Dorffel W, Ruhl U, Luders H, et al. Treatment of children and adolescents with Hodking lympha without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013;31:1562–8.CrossRefGoogle Scholar
  3. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: A report from Children’s Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651–8.CrossRefGoogle Scholar
  4. Hodgson DC, Dieckmann K, Terezakis S, et al. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Pract Radiat Oncol. 2015;5(2):85–92.CrossRefGoogle Scholar
  5. Hudson MM, Krasin N, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COPP and response-based, involved-field radiation for unfavorable pediatric Hodgkins disease. J Clin Oncol. 2004;22:4541–50.CrossRefGoogle Scholar
  6. Keller F, Castellino S, Constine L, et al. Intensive therapy free survival (ITFS) for early-stage Hodgkin lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy alone. Klin Padiatr. 2014;226:O_09CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • David R. Raleigh
    • 1
  • Daphne A. Haas-Kogan
    • 2
  • Steve E. Braunstein
    • 1
  1. 1.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA
  2. 2.Department of Radiation OncologyBrigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston Children’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations